FMR1 and fragile X-associated tremor/ataxia syndrome: Importantly, the genetic and pharmacologic approaches employed here suggest that these chromatin alterations are modifiable, indicating that the enhanced FMR1 mRNA expression in FXTAS patients could be a viable therapeutic target.